Advertisement

Ethics and Research with Pregnant Women: Lessons from HIV/AIDS

  • Margaret Olivia Little
  • Anne Drapkin Lyerly
  • Anna C. Mastroianni
  • Ruth R. Faden
Part of the Research Ethics Forum book series (REFF, volume 3)

Abstract

HIV/AIDS is among the most serious diseases confronting women who are pregnant. It is also one of the few areas of research involving humans where there is a long track record of research involving pregnant women. Yet the HIV/AIDS research community has struggled to expand the research agenda from research to prevent mother-to-child transmission of HIV to research encompassing issues pertaining to the pregnant woman’s own health. Research questions of interest include: which antiretrovirals are safest and most effective for pregnant women; how best to pursue preventive regimes for pregnant women who are not infected; or, how to treat HIV’s deadly co-infections, such as tuberculosis (TB), during pregnancy. In this chapter, we describe two key lessons about research in pregnancy from the context of HIV/AIDS: first, why addressing the health needs of pregnant women, not just the needs of their offspring, is so critical; and second, why doing so is immediately possible, even as we work to resolve certain ethical and regulatory debates, particularly about when it is appropriate to impose foetal risk without the prospect of foetal benefit. In particular, the HIV/AIDS context shows how treatment or prevention of maternal disease often entails not just risk – but the prospect of benefit – to the foetus; and creative trial designs can advance no-benefit studies without imposing foetal risk in the first place. For all the challenges that research with pregnant women entails, the HIV/AIDS context reveals that it is possible to conduct a wide range of important research during pregnancy that is both ethically responsible and consonant with US regulations.

Keywords

Pregnant women Clinical research Research ethics Pregnancy HIV/AIDS Women’s health Clinical trials 

References

  1. Abdool Karim, Q., S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996): 1168–1174.CrossRefPubMedPubMedCentralGoogle Scholar
  2. ACOG (American College of Obstetricians and Gynecologists). 2005. ACOG practice bulletin no. 60: Pregestational diabetes mellitus. Obstetrics and Gynecology 105(3): 675–685.CrossRefGoogle Scholar
  3. ACOG (American College of Obstetricians and Gynecologists). 2008. ACOG practice bulletin no. 92: Use of psychiatric medications during pregnancy and lactation. Obstetrics and Gynecology 111(4): 1001–1020.CrossRefGoogle Scholar
  4. AIDSInfo. 2014. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed 8 Apr 2016.
  5. Allen, V.M., and B.A. Armson for the SOGC Genetics Committee. 2007. SOGC clinical practice guideline – Teratology associated with pre-existing and gestational diabetes. Journal of Obstetrics and Gynaecology Canada 29(11): 927–944.Google Scholar
  6. Andrew, M.A., M.R. Easterling, D.B. Carr, D. Shen, D.L. Buchanan, T. Rutherford, et al. 2007. Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of dosage strategies. Clinical Pharmacology and Therapeutics 81(4): 547–556.Google Scholar
  7. Ashcroft, R. 2016. Ethical issues in a trial of maternal gene transfer to improve foetal growth. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 247–263. Cham: Springer.Google Scholar
  8. AVERT. 2014. Funding for HIV and AIDS. http://www.avert.org/funding-hiv-and-aids.htm. Accessed 8 Apr 2016.
  9. Baeten, J.M., D. Donnell, P. Ndase, N.R. Mugo, J.D. Campbell, J. Wangisi et al. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine 367(5): 399–410.Google Scholar
  10. Ballantyne, A., and W. Rogers. 2016. Pregnancy, vulnerability, and the risk of exploitation in clinical research. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 139–159. Cham: Springer.Google Scholar
  11. Beigi, R., L. Noguchi, T. Parsons, I. Macio, R.P. Kunjara, N. Ayudhya, et al. 2011. Pharmacokinetics and placental transfer of single-dose tenofovir 1 % vaginal gel in term pregnancy. The Journal of Infectious Diseases 204(10): 1527–1531.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Birkhead, G.S., W.P. Pulver, B.L. Warren, S. Hackel, D. Rodríguez, and L. Smith 2010. Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York. Obstetrics and Gynecology 115(6): 1247–1255.Google Scholar
  13. Blonk, M., A. Colbers, C. Hidalgo-Tenorio, K. Kabeya, K. Weizsäcker, A. Haberl, et al. 2015. Raltegravir in HIV-1 infected pregnant women: Pharmacokinetics, safety and efficacy. Clinical Infectious Diseases 61(5): 809–816.Google Scholar
  14. Brocklehurst, P., and R. French. 1998. The association between maternal HIV infection and perinatal outcome: A systematic review of the literature and meta-analysis. British Journal of Obstetrics and Gynaecology 105(8): 836–848.CrossRefPubMedGoogle Scholar
  15. CDC (Centers for Disease Control). 2014. HIV in pregnant women, infants and children. http://www.cdc.gov/hiv/risk/gender/pregnantwomen/facts/index.html. Accessed 8 Apr 2016.
  16. Chen, J.Y., H.J. Ribaudo, S. Souda, N. Parekh, A. Ogwu, S. Lockman, et al. 2012. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. The Journal of Infectious Diseases 206(11): 1695–1705.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Chi, B.H., M.R. Adler, O. Bolu, D. Mbori-Ngacha, D. K. Ekouevi, A. Gieselman, et al. 2012. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President’s Emergency Plan for AIDS Relief. JAIDS 15(60, Suppl 3): S78–S87.Google Scholar
  18. Churchyard, G.J., F. Scano, A.D. Grant, and R.E. Chaisson. 2007. Tuberculosis preventive therapy in the era of HIV infection: Overview and research priorities. The Journal of Infectious Diseases 196(Suppl. 1): S52–S62.CrossRefPubMedGoogle Scholar
  19. DHHS (US Department of Health and Human Services). 2009. Code of Federal Regulations: Title 45, Part 46, Protection of Human Subjects. http://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed 3 Oct 2016.
  20. Dimitrov, D., M. Boily, J. Marrazzo, R. Beigi, and E.R. Brown. 2013. Population-level benefits from providing effective HIV prevention means to pregnant women in high prevalence settings. PLoS ONE 8(9): e73770.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Dinh, T., K.P. Delaney, A. Goga, D. Jackson, C. Lombard, S. Woldesenbet, et al. 2015. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: A national population-based evaluation. PLoS ONE 10(5): e0125525.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Drake, A.L., A. Wagner, B. Richarson, and G. John-Stewart. 2014. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: A systematic review and meta-analysis. PLoS Medicine 11(2): e1001608.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Ekouevi, D.K., P.A. Coffie, E. Ouattara, R. Moh, C. Amani-Bosse, E. Mossou, et al. 2011. Pregnancy outcomes in women exposed to efavirenz and nevirapine: An appraisal of the IeDEA West Africa and ANRS databases, Abidjan, Côte d’Ivoire. JAIDS 56(2): 183–187.Google Scholar
  24. Ells, C., and C. Lyster. 2016. Research ethics review of drug trials targeting medical conditions of pregnant women. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 95–118. Cham: Springer.Google Scholar
  25. EWG (Environmental Working Group). 2005. Body burden: The pollution in newborns. A benchmark investigation of industrial chemicals, pollutants, and pesticides in umbilical cord blood. http://www.ewg.org/research/body-burden-pollution-newborns. Accessed 8 Apr 2016.
  26. Ford, N., A. Calmy, and L. Mofenson. 2011. Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis. AIDS 25(18): 2301–2304.CrossRefPubMedGoogle Scholar
  27. Gray, G.E. 2008. Walking the tightrope in prevention of mother-to-child transmission of HIV infection. Clinical Infectious Diseases 46(4): 622–624.CrossRefPubMedGoogle Scholar
  28. Gray, R.H., X. Li, G. Kigozi, D. Serwadda, H. Brahmbhatt, F. Wabwire-Mangen, et al. 2005. Increased risk of incident HIV during pregnancy in rakai, Uganda: A prospective study. The Lancet 366(9492): 1182–1188.CrossRefGoogle Scholar
  29. Gupta, A., U. Nayak, M. Ram, R. Bhosale, S. Patil, A. Basavraj, et al. 2007. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002–2005. Clinical Infectious Diseases 45(2): 241–249.CrossRefPubMedGoogle Scholar
  30. Gupta, A., J.S. Matthad, S.M. Abdel-Rahman, J.D. Albano, R. Botgros, V. Brown, et al. 2016. Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: Consensus statements from an international expert panel. TB drug trials: Consensus statements from an expert panel. Clinical Infectious Diseases 62(6): 761–769.CrossRefPubMedGoogle Scholar
  31. Healy, D., and D. Mangin. 2016. Does my bias look big in this? In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 197–208. Cham: Springer.Google Scholar
  32. HIV Prevention Trials Network. 2006. HPTN 035: Phase II/IIb safety and effectiveness study of the vaginal microbicides buffergel and 0.5 % pro 2000/5 gel (p) for the prevention of HIV infection in women. http://www.hptn.org/research_studies/hptn035.asp. Accessed 8 Apr 2016.
  33. Huybrechts, K.F., B.T. Bateman, K. Palmsten, R.J. Desai, E. Patorno, C. Gopalakrishnan, et al. 2015. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313(21): 2142–2151.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Johnson, L.S.M. 2016. When hypothetical vulnerability becomes actual: Research participation and the autonomy of pregnant women. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 161–178. Cham: Springer.Google Scholar
  35. Kelland, K. 2010. UNICEF says HIV-free generation is achievable. Reuters Health (London), 30 November. http://www.reuters.com/article/2010/11/30/us-aids-unicef-idUSTRE6AT3IC20101130. Accessed 8 Apr 2016.
  36. Krakower, D., and K.H. Mayer. 2011. Promising prevention approaches: Tenofovir gel and prophylactic use of antiretroviral edications. Current HIV/AIDS Reports 8(4): 241–248.CrossRefPubMedPubMedCentralGoogle Scholar
  37. Kukla, R. 2016. Equipoise, uncertainty, and inductive risk in research involving pregnant women. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 179–196. Cham: Springer.Google Scholar
  38. Lyerly, A., M. Little, and R. Faden. 2009. The National Children’s Study: A golden opportunity to advance the health of pregnant women? The American Journal of Public Health 99(10): 1742–1745.CrossRefPubMedGoogle Scholar
  39. Maternal Fetal Medicine Units Network. 2015. Research projects. https://mfmu.bsc.gwu.edu/research-projects. Accessed 8 Apr 2016.
  40. Merton, V. 1996. Ethical obstacles to women in biomedical research. In Feminism and bioethics: Beyond reproduction, ed. S. Wolf, 216–251. Oxford/New York: Oxford University Press.Google Scholar
  41. Microbicide Trials Network. 2008. MTN-003: Phase 2B safety and effectiveness study of tenofovir 1 % gel, tenofovir disoproxil fumarate tablet and emtricitabine/tenofovir disoproxil fumarate tablet for the prevention of HIV infection in women. http://www.mtnstopshiv.org/sites/default/files/attachments/MTN-003_FINAL_Version_2.0_31DEC2010.pdf. Accessed 8 Apr 2016.
  42. Mirochnick, M., and E. Capparelli. 2004. Pharmacokinetics of antiretrovirals in pregnant women. Clinical Pharmacokinetics 43(15): 1071–1087.CrossRefPubMedGoogle Scholar
  43. Mofenson, L., and B.E. Laughon. 2007. Human immunodeficiency virus, mycobacterium tuberculosis, and pregnancy: A deadly combination. Clinical Infectious Diseases 45(2): 250–253.CrossRefPubMedGoogle Scholar
  44. Moodley, D., T. Esterhuizen, T. Pather, V. Chetty, and L. Ngaleka. 2009. High HIV incidence during pregnancy: Compelling reason for repeat HIV testing. AIDS 23(10): 1255–1259.CrossRefPubMedGoogle Scholar
  45. Mugo, N.R., R. Heffron, D. Donnel, A. Wald, E.O. Were, H. Rees, et al. 2011. Increased risk of HIV-1 transmission in pregnancy: A prospective study among African HIV-1 serodiscordant couples. AIDS 25(15): 1887–1895.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Patterson, K.B., J.B. Dumond, H.A. Prince, A.J. Jenkins, K.K. Scarsi, R. Want, et al. 2013. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: Implications for treatment guidelines. JAIDS 63(1): 51–58.PubMedPubMedCentralGoogle Scholar
  47. Pearson, R.M., J. Evans, D. Kounali, G. Lewis, J. Heron, P.G. Ramchandani, et al. 2013. Maternal depression during pregnancy and the postnatal period: Risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry 70(12): 1312–1319.CrossRefPubMedPubMedCentralGoogle Scholar
  48. PhRMA – America’s Biopharmaceutical Research Companies. 2014. 2014 report – Medicines in development: HIV/AIDS. http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-hiv-aids.pdf. Accessed 8 Apr 2016.
  49. Presidential Commission for the Study of Bioethical Issues. 2011. “Ethically impossible”: STD research in Guatamala from 1946 to 1948. http://bioethics.gov/sites/default/files/Ethically-Impossible_PCSBI.pdf. Accessed 8 Apr 2016.
  50. Raymond, E.G., D. Taylor, W. Cates Jr., E.E. Tolley, D. Borasky, A. Cancel, et al. 2007. Pregnancy in effectiveness trials of HIV prevention agents. Sexually Transmitted Diseases 34(12): 1035–1039.PubMedGoogle Scholar
  51. Shah, S., A. Whittle, B. Wilfond, G. Gensler, and D. Wendler. 2004. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA 291(4): 476–482.CrossRefPubMedGoogle Scholar
  52. Shearer, K., A.T. Brennan, M. Maskew, L. Long, R. Berhanu, I. Sanne, and M.P. Fox. 2014. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. Journal of the International AIDS Society 17(1): 19065.CrossRefPubMedPubMedCentralGoogle Scholar
  53. Sibeko, S., C. Baxter, N. Yende, Q. Abdool Karim, and S.S. Abdool Karim. 2011. Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstetrics and Gynecology 118(4): 895–904.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Simon, A., J. Warszawski, D. Kariyawasam, J. Le Chenadec, V. Benhammou, P. Czernichow, et al. 2011. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 306(1): 70–78.CrossRefPubMedGoogle Scholar
  55. Spencer, B. 2015. Taking antidepressants during pregnancy increases risk of baby developing a rare circulation problem which causes permanent disabilities. Daily Mail, 2 June. http://www.dailymail.co.uk/health/article-3107709/Taking-antidepressants-pregnancy-increases-risk-baby-developing-rare-circulation-problem-causes-permanent-disabilities.html. Accessed 8 Apr 2016.
  56. Strong, C. 2011a. How should risks and benefits be balanced in research involving pregnant women and fetuses? IRB 33(6): 1–5.PubMedPubMedCentralGoogle Scholar
  57. Strong, C. 2011b. Minimal risk in research involving pregnant women and fetuses. The Journal of Law, Medicine & Ethics 39(3): 529–538.CrossRefGoogle Scholar
  58. UNAIDS. 2014. 2014 progress report on the global plan. http://www.unaids.org/sites/default/files/documents/JC2681_2014-Global-Plan-progress_en.pdf. Accessed 8 Apr 2016.
  59. Wang, L., A.P. Kourtis, S. Ellington, J. Legardy-Williams, and M. Bulterys. 2013. Safety of tenofovir during pregnancy for the mother and fetus: A systematic review. Clinical Infectious Diseases 57(12): 1773–1781.CrossRefPubMedGoogle Scholar
  60. Watts, H.D., A. Stek, B.M. Best, J. Wang, E.V. Capparelli, T.R. Cressey, et al. 2014. Raltegravir pharmacokinetics during pregnancy. JAIDS 67(4): 375–381.PubMedPubMedCentralGoogle Scholar
  61. Wendler, D. 2005. Protecting subjects who cannot give consent: Toward a better standard for “minimal” risks. Hastings Center Report 35(5): 37–43.CrossRefPubMedGoogle Scholar
  62. Westra, A.E., J.M. Wit, R.M. Sukhai, and I.D. de Beaufort. 2011. How best to define the concept of minimal risk. The Journal of Pediatrics 159(3): 496–500.CrossRefPubMedGoogle Scholar
  63. WHO (World Health Organization). 2014. Global guidance on criteria and processes for validation: Elimination of maternal to child transmission (EMTCT) of HIV and syphilis. http://apps.who.int/iris/bitstream/10665/112858/1/9789241505888_eng.pdf?ua=1&ua=1. Accessed 8 Apr 2016.
  64. WHO (World Health Organization). 2015. Mother to child transmission of HIV. http://www.who.int/hiv/topics/mtct/en/. Accessed 8 Apr 2016.
  65. Wild, V., and N. Biller-Andorno. 2016. Pregnant women’s views about participation in clinical research. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 119–136. Cham: Springer.Google Scholar
  66. Wilson, R.D., and The SOGC Genetics Committee. 2007. Principles of human teratology: Drug, chemical and infectious exposure. SOGC clinical practice guideline. Journal of Obstetrics and Gynaecology Canada 29(11): 911–917.CrossRefPubMedGoogle Scholar
  67. Yeh, R.F., N.L. Rezk, A.D. Kashuba, J.B. Dumond, H.L. Tappouni, H.C. Tien, et al. 2009. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrobial Agents and Chemotherapy 53(6): 2367–2374.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Margaret Olivia Little
    • 1
  • Anne Drapkin Lyerly
    • 2
  • Anna C. Mastroianni
    • 3
  • Ruth R. Faden
    • 4
  1. 1.Kennedy Institute of EthicsGeorgetown UniversityWashington, DCUSA
  2. 2.Center for Bioethics, Department of Social MedicineUniversity of North Carolina at Chapel HillChapel HillUSA
  3. 3.University of Washington School of LawSeattleUSA
  4. 4.Johns Hopkins Berman Institute of BioethicsBaltimoreUSA

Personalised recommendations